Terumo (4543) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
8 Jan, 2026Executive summary
Achieved record-high revenue and profit for Q3 and the cumulative period, with 13.1% year-over-year revenue growth to ¥772.2 billion, driven by strong global demand, especially in the US, and favorable foreign exchange effects.
Profit growth outpaced sales growth due to effective pricing, profitability improvements, and operational measures.
Adjusted operating profit increased 33.0% to ¥159.3 billion, with net profit attributable to owners up 23.4% to ¥98.6 billion.
One-time restructuring and impairment costs were recorded, but underlying business momentum remains strong.
Financial highlights
Cumulative Q3 revenue reached ¥772.2 billion, with operating income at ¥133.5 billion and adjusted operating income at ¥159.3 billion.
Gross profit margin improved to 54.7% for Q3 YTD (from 52.0%), with Q3 margin at 55.1%.
Free cash flow for Q3 YTD was ¥93.9 billion, up ¥55.8 billion year-over-year.
Basic earnings per share was ¥66.53, up from ¥53.66, reflecting a two-for-one share split effective April 1, 2024.
Cash and cash equivalents at period end: ¥212.6 billion.
Outlook and guidance
Full-year and FY2025 guidance remain unchanged, with revenue guidance at ¥1,010 billion and adjusted operating profit at ¥200 billion.
Management will focus on high value-added products, cost improvements, and SG&A efficiency amid industry and FX uncertainties.
Restructuring and extraordinary costs are expected to be one-off and not to recur in the next fiscal year.
FY24 guidance for CAPEX at ¥93 billion and R&D expenses at ¥71.5 billion.
Management continues to monitor macro risks such as raw material prices and U.S. tariff policies.
Latest events from Terumo
- Record revenue and profit growth, driven by global demand and strategic acquisitions.4543
Q3 202613 Feb 2026 - Record revenue and profit growth, with double-digit gains and improved margins.4543
Q1 20252 Feb 2026 - Record sales and profit surge drive raised guidance, innovation, and share split.4543
Q2 202516 Jan 2026 - Innovation, M&A, and new launches fuel global growth and margin expansion.4543
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - $1.5B acquisition accelerates entry into organ transplantation, driving growth and innovation.4543
M&A Announcement23 Nov 2025 - Record revenue and profit, global expansion, and strategic investments; tariff risks persist.4543
Q4 202517 Nov 2025 - Record revenue and profit growth, upward guidance, but lower OP due to acquisition costs.4543
Q2 202614 Nov 2025 - Record profit and revenue growth, led by US, China, and plasma innovation segments.4543
Q1 20267 Aug 2025